Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cardiff Oncology stock

Learn how to easily invest in Cardiff Oncology stock.

Cardiff Oncology Inc is a biotechnology business based in the US. Cardiff Oncology shares (CRDF) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiff Oncology employs 22 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cardiff Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRDF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Cardiff Oncology stock price (NASDAQ: CRDF)

Use our graph to track the performance of CRDF stocks over time.

Cardiff Oncology shares at a glance

Information last updated 2022-06-24.
Latest market close$2.20
52-week range$1.13 - $8.58
50-day moving average $1.51
200-day moving average $4.05
Wall St. target price$12.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.84

Buy Cardiff Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cardiff Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cardiff Oncology price performance over time

Historical closes compared with the close of $2.2 from 2022-06-30

1 week (2022-06-24) -3.08%
1 month (2022-06-01) 78.86%
3 months (2022-04-01) -11.65%
6 months (2021-12-31) -63.39%
1 year (2021-07-01) -66.92%
2 years (2020-07-01) -53.78%
3 years (2019-07-01) 2.52
5 years (2017-06-30) 74.60%

Cardiff Oncology financials

Revenue TTM $361,000
Gross profit TTM $-17,017,000
Return on assets TTM -16.04%
Return on equity TTM -26.76%
Profit margin 0%
Book value $3.00
Market capitalisation $99.2 million

TTM: trailing 12 months

Cardiff Oncology share dividends

We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.

Have Cardiff Oncology's shares ever split?

Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.

Cardiff Oncology share price volatility

Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $1.13 up to $8.58. A popular way to gauge a stock's volatility is its "beta".

CRDF.US volatility(beta: 2.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 2.0304. This would suggest that Cardiff Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cardiff Oncology overview

Cardiff Oncology, Inc. , a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc.

Frequently asked questions

What percentage of Cardiff Oncology is owned by insiders or institutions?
Currently 7.123% of Cardiff Oncology shares are held by insiders and 43.36% by institutions.
How many people work for Cardiff Oncology?
Latest data suggests 22 work at Cardiff Oncology.
When does the fiscal year end for Cardiff Oncology?
Cardiff Oncology's fiscal year ends in December.
Where is Cardiff Oncology based?
Cardiff Oncology's address is: 11055 Flintkote Avenue, San Diego, CA, United States, 92121
What is Cardiff Oncology's ISIN number?
Cardiff Oncology's international securities identification number is: US14147L1089
What is Cardiff Oncology's CUSIP number?
Cardiff Oncology's Committee on Uniform Securities Identification Procedures number is: 897238101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site